antaitavir hasophate + yiqibuvir

A fixed-dose oral combination of **antaitavir hasophate** and **yiqibuvir** developed for the treatment of **chronic hepatitis C virus (HCV) infection** in adults, including those with genotypes 1, 2, 3, and 6, with or without compensated cirrhosis, both in treatment-naive and treatment-experienced patients. Both agents act as **direct-acting antivirals** with distinct antiviral targets; antaitavir hasophate is described as an **imidazole derivative** (specific mechanistic class unspecified in literature), while yiqibuvir is reported as an antiviral targeting HCV replication. Clinical studies demonstrate high sustained virologic response rates and good safety profile, with most adverse events being mild. The combination is administered orally, once daily, in studies over 12-week periods, and has reached phase III clinical trial status in China[1][3][5][6].

Brand names

Antaitavir

Other names

antaitasvir phosphate + yiqibuvir